Online inquiry

IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 0, 2-Thio-UTP, 120 nt-poly(A))   (CAT#: GTTS-WQ13827MR)

This product GTTS-WQ13827MR is a type of mRNA having 120 nt poly(A) tail and modified with Cap 0 & 2-Thio-UTP. It ecodes the monoclonal antibody that targets S gene. The antibody can be applied in Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection (COVID-19) research.
Specifications
Product type mRNA
Modified bases 2-Thio-UTP
5' Cap Cap 0
Species Homo sapiens
RefSeq YP_009724390.1
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 43740568
UniProt ID P59594
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-S, REGN-10987(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) (GTTS-WQ13827MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ6091MR IVTScrip™ mRNA-Anti-IL23A, CNTO-1959(Cap 0, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA CNTO-1959
GTTS-WQ14979MR IVTScrip™ mRNA-Anti-IL17A, SHR-1314(Cap 0, 2-Thio-UTP, 120 nt-poly(A)) mRNA SHR-1314
GTTS-WQ3604MR IVTScrip™ mRNA-Anti-LYPD3, BAY 1129980(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA BAY 1129980
GTTS-WQ4589MR IVTScrip™ mRNA-Anti-CD40LG, BMS-986004(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA BMS-986004
GTTS-WQ4146MR IVTScrip™ mRNA-Anti-PDCD1, BI-754091(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA BI-754091
GTTS-WQ14904MR IVTScrip™ mRNA-Anti-stx2 A-subunit, Shigamabs®(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA Shigamabs®
GTTS-WQ3070MR IVTScrip™ mRNA-Anti-TFPI, Anti-TFPI(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA Anti-TFPI
GTTS-WQ9536MR IVTScrip™ mRNA-Anti-FOLH1, J-591(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA J-591
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW